Efficacy and Safety of Antiplatelet Therapy After Endovascular Aortic Repair
EVAR_DAPT_SAPT
A Target Trial Emulation for Efficacy and Safety of Antiplatelet Therapy After Endovascular Aortic Repair
1 other identifier
observational
8,325
0 countries
N/A
Brief Summary
This study was a target trial emulation using the National Health Claims database established by the Korean National Health Insurance Service (K-NHIS). 8,325 patients were included.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2003
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2003
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
September 30, 2023
CompletedFirst Submitted
Initial submission to the registry
March 10, 2025
CompletedFirst Posted
Study publicly available on registry
March 14, 2025
CompletedMarch 14, 2025
March 1, 2025
20.8 years
March 10, 2025
March 10, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Major adverse cardiac and cerebrovascular events (MACCE)
composite of all-cause death, myocardial infarction (MI), or ischemic stroke
1 year after EVAR
Major or clinically relevant non-major bleeding
Diagnostic codes in the primary or secondary position and transfusion receipt
1 year after EVAR
Re-intervention or surgery for AAAs
Re-intervention or surgery for AAAs
1 year after EVAR
Study Arms (2)
Dual antiplatelet therapy
Patients who were prescribed dual antiplatelet therapy at the date of discharge from the index hospitalization for standard EVAR
Single antiplatelet therapy
Patients who were prescribed single antiplatelet therapy at the date of discharge from the index hospitalization for standard EVAR
Eligibility Criteria
All patients who underwent EVAR for AAA and were successfully discharged and prescribe any antiplatelet therapy.
You may qualify if:
- All patients who underwent EVAR for AAA and were successfully discharged
You may not qualify if:
- Patients who had experienced a myocardial infarction
- Patients who had experienced a stroke
- Patients who had experienced percutaneous coronary intervention
- Patients who had history of peripheral disease
- Patients who had major bleeding event within 1 year of admission
- Those prescribed non-vitamin K antagonist oral anticoagulant or warfarin
- Patients who did not prescribe any antiplatelet therapy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Choi KH, Kang D, Nam J, Park TK, Song MG, Seo TS, Yang WJ, Choi SH. Efficacy and Safety of Antiplatelet Therapy After Endovascular Aortic Repair: A Target Trial Emulation. J Am Heart Assoc. 2025 Oct 21;14(20):e044102. doi: 10.1161/JAHA.125.044102. Epub 2025 Oct 9.
PMID: 41065286DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
March 10, 2025
First Posted
March 14, 2025
Study Start
January 1, 2003
Primary Completion
September 30, 2023
Study Completion
September 30, 2023
Last Updated
March 14, 2025
Record last verified: 2025-03
Data Sharing
- IPD Sharing
- Will not share